The price of Zituvio, a treatment for anemia, is not publicly disclosed by its manufacturer, Chiesi Farmaceutici. Pricing for prescription medications can vary significantly based on factors such as insurance coverage, pharmacy, and geographic location. For specific pricing information, individuals should consult their healthcare provider or local pharmacy [1].
What is Zituvio used for?
Zituvio (Roxadustat) is a medication used to treat anemia in adults who have chronic kidney disease (CKD) [1]. It is a hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor, which works by stimulating the body's natural response to low oxygen levels, thereby increasing red blood cell production [2].
When will Zituvio's patent expire?
Information regarding the specific patent expiry dates for Zituvio is not readily available in the public domain. Patent protection for pharmaceutical products is complex and can involve multiple patents covering the drug substance, formulation, and methods of use. For detailed patent information, resources like DrugPatentWatch.com may provide further insights [3].
How does Zituvio compare to other anemia treatments?
Zituvio belongs to a class of drugs called HIF-PH inhibitors, which offer an alternative to traditional erythropoiesis-stimulating agents (ESAs) for managing anemia in CKD patients. ESAs, such as epoetin alfa and darbepoetin alfa, directly stimulate the bone marrow to produce red blood cells. HIF-PH inhibitors, like Zituvio, work by mimicking the body's response to hypoxia, leading to increased erythropoietin production and improved red blood cell count [2][4]. Clinical studies have explored the efficacy and safety profiles of HIF-PH inhibitors in comparison to ESAs [4].
What are the potential side effects of Zituvio?
Common side effects associated with Zituvio can include hypertension, thrombosis (blood clots), and hyperkalemia (high potassium levels). Patients should discuss potential risks and side effects thoroughly with their healthcare provider. It is important for individuals to report any new or worsening symptoms to their doctor promptly [1].
Who makes Zituvio?
Zituvio is manufactured by Chiesi Farmaceutici [1].
Can biosimilars of Zituvio be developed?
The development of biosimilars for complex biologic drugs can be a lengthy and intricate process. For small molecule drugs like Zituvio, the pathway for generic or biosimilar competition is generally based on patent expiry and regulatory approval pathways. Specific timelines and possibilities for generic or biosimilar entry would depend on patent landscapes and regulatory considerations [3].
---
Sources:
1. https://www.drugpatentwatch.com/drug/zituvio
2. https://www.drugpatentwatch.com/drug/roxadustat
3. https://www.drugpatentwatch.com/
4. https://pubmed.ncbi.nlm.nih.gov/34536905/